NK cells, as a type of innate lymphoid cell that is primarily involved in early pathogen infection control and anti-tumour immunity, have also been explored and developed as another cell source for targeting MM with anti-BCMA CAR constructs [68,69,70]. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.